<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05099939</url>
  </required_header>
  <id_info>
    <org_study_id>ProspeC-F</org_study_id>
    <nct_id>NCT05099939</nct_id>
  </id_info>
  <brief_title>Identification of Dysglycemia With Continuous Glucose Monitoring to Assess Clinical Evolution in Cystic Fibrosis</brief_title>
  <acronym>ProspeC-F</acronym>
  <official_title>Identification of Dysglycemia With Continuous Glucose Monitoring: A Prospective Study to Assess the Relationship With Clinical Evolution in Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Recherches Cliniques de Montreal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre hospitalier de l'Université de Montréal (CHUM)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Lyon Sud</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondation Francophone pour la Recherche sur le Diabete</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut de Recherches Cliniques de Montreal</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cystic fibrosis (CF)-related diabetes (CFRD) is the most important emerging complication&#xD;
      after pulmonary complications. This specific form of diabetes is associated with an increased&#xD;
      morbidity and mortality. CFRD prevalence at the age of 10 is 10% and reaches 40 to 50% in&#xD;
      adulthood, while a similar percentage is afflicted with milder dysglycemia also called&#xD;
      pre-diabetes abnormalities.&#xD;
&#xD;
      In order to identify patients at risk and to implement early therapeutic measures, an annual&#xD;
      CFRD screening test is recommended for CF patients after 10 years of age. The standard 2-hour&#xD;
      oral glucose tolerance test (OGTT) is the recommended screening test. However, this test is&#xD;
      perceived by both patients and CF care teams as unpleasant while adding a significant burden&#xD;
      and workload, resulting in screening rates lower than 50% in most centers. An ideal&#xD;
      alternative test should be simpler, less invasive, more sensitive than an OGTT to establish&#xD;
      risks for lung function and/or nutritional deterioration, and predict future CFRD risk. To&#xD;
      date, compared to the OGTT, no alternative screening method has demonstrated its&#xD;
      effectiveness. However, continuous glucose monitoring (CGM) is emerging as a possible&#xD;
      alternative method.&#xD;
&#xD;
      In patients living with CF, CGM is easy to use and can identify early dysglycemia, which in&#xD;
      turn, can predict increased risk of accelerated decline of pulmonary function and/or weight,&#xD;
      higher risk of pseudomonas colonization, and future risk of CFRD. However, these observations&#xD;
      are based on studies of small sample size with very limited prospective data. Furthermore,&#xD;
      many of the multiple CGM metrics that have been standardized are based on the risk of&#xD;
      complications associated with Type 1 and Type 2 Diabetes.&#xD;
&#xD;
      Thus, there is a need for prospective studies to identify the CGM metrics and the cut-off&#xD;
      level that is relevant as a predictor of clinical deterioration and/or CFRD risk in CF. The&#xD;
      identification of such CF-specific criteria would provide important information to target&#xD;
      at-risk patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators propose an international multicenter observational study to evaluate the&#xD;
      predictive value of CGM variables on the evolution of the clinical state in adult patients&#xD;
      with CF.&#xD;
&#xD;
      To do this, the following will be evaluated:&#xD;
&#xD;
        -  The clinical condition of the patients over a period of 5 years (2 years before, up to 3&#xD;
           years after inclusion);&#xD;
&#xD;
        -  The detailed glycemic profile using a CGM system during 3 visits (on inclusion, 1 year,&#xD;
           then 2 years after inclusion).&#xD;
&#xD;
      The primary objective is to identify which CGM variable, at inclusion in the study, is the&#xD;
      most strongly linked to the risk of a decrease in pulmonary function of more than 2% / year&#xD;
      measured by the FEV1% over the 5 years of follow-up of the study. The investigators will also&#xD;
      i) investigate which CGM variables are most strongly linked to other clinical markers (ex.&#xD;
      nutritional status, CFRD diagnosis and pulmonary exacerbations; ii) assess the association&#xD;
      between changes in CGM variables (ex. increased number of glycemic excursions &gt;11.0 mmol/L&#xD;
      over 2 years) and changes in clinical status over time; and iii) evaluate the correlation&#xD;
      between plasma glucose values during the standard routine OGTT and CGM values.&#xD;
&#xD;
      This study includes 3 visits with participants: inclusion (V1), the visit at 1 year (V2),&#xD;
      then 2 years after inclusion (V3).&#xD;
&#xD;
      This study consists of 3 phases:&#xD;
&#xD;
        -  Phase 1: A retrospective file-based data collection, which covers 2 years before&#xD;
           inclusion;&#xD;
&#xD;
        -  Phase 2: Prospective data collection, including the installation of a CMG 3 times over a&#xD;
           period of 2 years, then;&#xD;
&#xD;
        -  Phase 3: An additional one-year prospective data collection on file only.&#xD;
&#xD;
      Only phase 2 includes visits for the participant. A CMG system will be installed for 14 days&#xD;
      at inclusion (visit 1), at 1 year (visit 2) and 2 years (visit 3) during a regular routine&#xD;
      visit and / or an annual OGTT visit. The participants' only involvement will be to wear the&#xD;
      CMG system and return it to the research center at the end of the 14-day period. All data&#xD;
      obtained during a routine visit will be collected directly from medical records over a period&#xD;
      of 5 years (two years before inclusion until the final visit): pulmonary function (FEV1),&#xD;
      nutritional status (weight and height), bronchial colonization by Pseudomonas aeruginosa,&#xD;
      number of exacerbations, number of intravenous antibiotic courses, number of&#xD;
      hospitalizations, and annual OGTT results.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">July 2026</completion_date>
  <primary_completion_date type="Anticipated">July 2026</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Change in lung function</measure>
    <time_frame>5 years</time_frame>
    <description>The primary outcome is the mean annual rate of change in lung function (FEV1%) from 2 years before inclusion to 3 years later, for a total of 5 years of follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in body mass index</measure>
    <time_frame>2 years</time_frame>
    <description>Change in body mass index weight category from inclusion to 2 years (underweight, adequate weight, overweight).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of pulmonary exacerbations</measure>
    <time_frame>1 year</time_frame>
    <description>Average annual number of pulmonary exacerbations per year (validated Fuchs questionnaire), including exacerbations that are treated at home or at the hospital.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CFRD diagnosis</measure>
    <time_frame>3 years</time_frame>
    <description>Development of new cases of CFRD diagnosed with standard OGTT and initiation of all anti-diabetic treatment.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">121</enrollment>
  <condition>Cystic Fibrosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Adult individuals living with cystic fibrosis who are being followed at the following&#xD;
        centers: Centre Hospitalier de l'Université de Montréal (CHUM), Université de Lyon&#xD;
        (Hospices Civils de Lyon) and Université de Strasbourg (CHU de Strasbourg).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have cystic fibrosis&#xD;
&#xD;
          -  Be 18 years of age or older&#xD;
&#xD;
          -  Have given clear and informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Receive pharmaceutical treatment for diabetes&#xD;
&#xD;
          -  Have had a lung or liver transplant&#xD;
&#xD;
          -  Participate in a randomized controlled trial for more than 3 months in parallel with&#xD;
             this study&#xD;
&#xD;
          -  Currently pregnant&#xD;
&#xD;
          -  Patients under legal protection (for centers in France)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rémi Rabasa-Lhoret</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de recherches cliniques de Montréal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laurence Kessler</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Strasbourg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Isabelle Durieu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katherine Desjardins</last_name>
    <phone>5149875666</phone>
    <email>katherine.desjardins@ircm.qc.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut de recherches cliniques de Montréal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1R7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Université de Montréal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 3E4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Remi Rabasa-Lhoret</last_name>
      <phone>5149875500</phone>
      <phone_ext>3227</phone_ext>
    </contact>
    <investigator>
      <last_name>Rémi Rabasa-Lhoret</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Isabelle Durieu</last_name>
      <email>isabelle.durieu@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle Durieu</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Quitterie Reynaud</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Laurence Kessler</last_name>
      <phone>03 88 11 65 98</phone>
      <email>Laurence.Kessler@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Laurence Kessler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 19, 2021</study_first_submitted>
  <study_first_submitted_qc>October 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Screening Test</keyword>
  <keyword>Continuous glucose monitoring</keyword>
  <keyword>Oral glucose tolerance test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

